BioLargo, Inc. BLGO
$0.09
$0.00-1.97%
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -70.95% | -65.55% | -56.33% | -41.57% | -16.42% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -70.95% | -65.55% | -56.33% | -41.57% | -16.42% |
| Cost of Revenue | -68.07% | -64.84% | -56.11% | -43.94% | -13.88% |
| Gross Profit | -74.41% | -66.48% | -56.60% | -38.59% | -19.29% |
| SG&A Expenses | 66.02% | 64.41% | 68.21% | 64.32% | 8.19% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 8.81% | 0.35% | 2.24% | 6.63% | -0.88% |
| Operating Income | -185.59% | -198.08% | -242.75% | -274.74% | -68.64% |
| Income Before Tax | -184.93% | -203.53% | -249.41% | -251.55% | -61.52% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -184.93% | -203.53% | -249.41% | -251.55% | -61.52% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 59.66% | 60.40% | 75.32% | 93.61% | 106.98% |
| Net Income | -271.60% | -310.23% | -390.38% | -364.81% | -40.22% |
| EBIT | -185.59% | -198.08% | -242.75% | -274.74% | -68.64% |
| EBITDA | -191.16% | -205.37% | -250.70% | -282.91% | -69.20% |
| EPS Basic | -258.14% | -295.24% | -370.37% | -345.83% | -34.38% |
| Normalized Basic EPS | -404.26% | -463.16% | -600.00% | -763.16% | -30.56% |
| EPS Diluted | -258.14% | -295.24% | -370.37% | -345.83% | -34.38% |
| Normalized Diluted EPS | -404.26% | -463.16% | -600.00% | -763.16% | -30.56% |
| Average Basic Shares Outstanding | 4.71% | 3.81% | 2.96% | 2.82% | 3.19% |
| Average Diluted Shares Outstanding | 4.71% | 3.81% | 2.96% | 2.82% | 3.19% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |